In melanoma, a vaccine for CSCs developed by Yin et al. et al. promotes DC maturation, activates CD8+ T cells, inhibits the expression of CTLA-4, PD-1, and Tim-3, as well as upregulates the expression of IFN-γ and GzmB in CD8+ T lymphocytes. Here, CD8A is linked to melanoma.